Long-term (4 years) experience of Nintedanib in IPF patients in Crete: A real life data study
K. Antoniou (Herakleion, Greece), A. Trachalaki (Herakleion, Greece), E. Vasarmidi (Herakleion, Greece), G. Margaritopoulos (London, United Kingdom), G. Papastratigakis (Herakleion, Greece), E. Bibaki (Herakleion, Greece), E. Stamataki (Herakleion, Greece), G. Meletis (Herakleion, Greece), N. Tzanakis (Herakleion, Greece)
Source: International Congress 2018 – Management of idiopathic interstitial pneumonias: established and new treatments
Disease area: Interstitial lung diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Antoniou (Herakleion, Greece), A. Trachalaki (Herakleion, Greece), E. Vasarmidi (Herakleion, Greece), G. Margaritopoulos (London, United Kingdom), G. Papastratigakis (Herakleion, Greece), E. Bibaki (Herakleion, Greece), E. Stamataki (Herakleion, Greece), G. Meletis (Herakleion, Greece), N. Tzanakis (Herakleion, Greece). Long-term (4 years) experience of Nintedanib in IPF patients in Crete: A real life data study. 4787
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you: